MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Corcept Therapeutics Incorporated DSO Ratio 2011-2026 | CORT
Annual DSO Ratio Corcept Therapeutics Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.7 | 27.3 | 26.6 | 26.8 | 23.8 | 23.7 | 25.6 | 64.6 | 44.3 | 45.2 | 45.8 | 50.3 | 61.5 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 64.6 | 23.7 | 37.8 |
Quarterly DSO Ratio Corcept Therapeutics Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.5 | 29.7 | 35.3 | 28.4 | 32.1 | 29.9 | 24.8 | 25.2 | 14.1 | - | 13.2 | 12 | 26.7 | - | 25.7 | 24.8 | 27.8 | 27.9 | 27.7 | 27 | 22.6 | 20.7 | 22.3 | 25.2 | 26.4 | 24 | 24.9 | 25.8 | 26 | 26.2 | 32.6 | 39.3 | 41.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 41.6 | 12 | 26.4 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adaptive Biotechnologies Corporation
ADPT
|
81.3 | $ 18.24 | -1.41 % | $ 2.68 B |  USA |
 |
Amgen
AMGN
|
76.7 | $ 344.45 | 0.75 % | $ 185 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 73.14 | 5.5 % | $ 9.78 B | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Biogen
BIIB
|
57.9 | $ 178.43 | -0.81 % | $ 26 B | USA |
 |
Aytu BioScience
AYTU
|
150 | $ 2.7 | 3.85 % | $ 17 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Adagene
ADAG
|
53.8 | $ 2.87 | 4.36 % | $ 162 M | China |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.11 | -2.05 % | $ 7.48 B |  Australia |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
74.6 | $ 1.39 | -1.42 % | $ 261 M | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 222.86 | -1.43 % | $ 5 B |  Danmark |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 4.12 | 2.74 % | $ 8.96 B |  Israel |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Cardiff Oncology
CRDF
|
284 | $ 1.75 | -0.29 % | $ 83.4 M | USA |
 |
Compugen Ltd.
CGEN
|
60.8 | $ 1.85 | 0.54 % | $ 166 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | Britain |
 |
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
55.7 | $ 14.11 | 3.14 % | $ 4.36 B | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
BioCryst Pharmaceuticals
BCRX
|
55.1 | $ 6.64 | 0.91 % | $ 1.37 B | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |